TW202126305A - 使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症 - Google Patents

使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症 Download PDF

Info

Publication number
TW202126305A
TW202126305A TW109132919A TW109132919A TW202126305A TW 202126305 A TW202126305 A TW 202126305A TW 109132919 A TW109132919 A TW 109132919A TW 109132919 A TW109132919 A TW 109132919A TW 202126305 A TW202126305 A TW 202126305A
Authority
TW
Taiwan
Prior art keywords
formula
cancer
egfr
methyl
hydrogen
Prior art date
Application number
TW109132919A
Other languages
English (en)
Chinese (zh)
Inventor
邁克爾 尼古拉斯 格雷科
邁克爾 約翰 科斯坦佐
邁克爾 阿蘭 格林
東 張
繼榮 彭
Original Assignee
美商貝達醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商貝達醫藥公司 filed Critical 美商貝達醫藥公司
Publication of TW202126305A publication Critical patent/TW202126305A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109132919A 2019-09-23 2020-09-23 使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症 TW202126305A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962904567P 2019-09-23 2019-09-23
US62/904,567 2019-09-23

Publications (1)

Publication Number Publication Date
TW202126305A true TW202126305A (zh) 2021-07-16

Family

ID=75166417

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109132919A TW202126305A (zh) 2019-09-23 2020-09-23 使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症

Country Status (7)

Country Link
US (1) US12390464B2 (https=)
EP (1) EP4034121A4 (https=)
JP (1) JP2022549272A (https=)
CN (1) CN114430681A (https=)
AU (1) AU2020352528A1 (https=)
TW (1) TW202126305A (https=)
WO (1) WO2021061695A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954298A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6709786B2 (ja) * 2014-12-11 2020-06-17 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
US20190275049A1 (en) * 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS

Also Published As

Publication number Publication date
US12390464B2 (en) 2025-08-19
WO2021061695A1 (en) 2021-04-01
US20220347177A1 (en) 2022-11-03
JP2022549272A (ja) 2022-11-24
AU2020352528A1 (en) 2022-04-21
EP4034121A4 (en) 2023-10-18
CN114430681A (zh) 2022-05-03
EP4034121A1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
TWI726363B (zh) Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法
TWI808958B (zh) 涉及二芳基巨環化合物之組合療法
CN111214471B (zh) 药物组合物及其用途
TW202529768A (zh) 癌症治療的療法
KR20160100975A (ko) 제약 조합물
CN103889422A (zh) 治疗胃肠道间质瘤的方法
TW202133856A (zh) 涉及二芳基巨環化合物之組合療法
JP2017214387A (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
JP2007502807A (ja) Ｅｒｂｂ２抗がん剤の投与スケジュール
CN114366743A (zh) 具有驱动致癌突变的癌症的治疗
JP2018090566A (ja) 非小細胞肺癌の治療のためのｅｇｆｒ ｔ７９０ｍ阻害剤およびｃｄｋ阻害剤の組合せ
JP2021525244A (ja) 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
JP2019048822A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2012526772A (ja) ホスホイノシチド３−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
JP7046250B2 (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
TW202126305A (zh) 使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症
KR20200135743A (ko) 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
TW202137982A (zh) 藥物組合及其用途
TWI623315B (zh) ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮及ｅｇｆｒ ｔｙｒ激酶抑制劑之新穎結合物
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
HK40095032B (zh) 一种药物组合物及其在治疗癌症中的用途
HK40095032A (zh) 一种药物组合物及其在治疗癌症中的用途
WO2012026511A1 (ja) 医薬組成物